In this issue:
Nivolumab combo enhances pCR rate in high-risk ER+ breast cancer
Neoadjuvant pembrolizumab beneficial in ER+/HER2- breast cancer
Ivonescimab prolongs PFS vs pembrolizumab in PD-L1-positive NSCLC
Aspirin fails to reduce risk of resected colorectal cancer recurrence
Trifluridine-tipiracil may be an efficacious later-line therapy for metastatic breast cancer
Limited activity of darolutamide in advanced AR+ TNBC
CIREL investigates real-world effectiveness of irinotecan-TACE for CRLMs
Abemaciclib + fulvestrant for progressive breast cancer after CDK4/6 inhibition
Nivolumab combo improves survival in advanced melanoma
Ivosidenib efficacious for IDH1-mutated cholangiocarcinoma
Please login below to download this issue (PDF)